Literature DB >> 31089680

Downregulation of long non-coding RNA MEG3 promotes proliferation, migration, and invasion of human hepatocellular carcinoma cells by upregulating TGF-β1.

Hui Dong1, Yue Zhang2, Yan Xu1, Ruixia Ma1, Liqiu Liu1, Congjuan Luo1, Wei Jiang1.   

Abstract

Hepatocellular carcinoma is a common malignant cancer with high incidence. And long non-coding RNAs (lncRNAs) play pivotal roles in the development of different types of cancers. In this study, we aimed to investigate the role of lncRNA maternally expressed gene 3 (MEG3) in the development and progression of hepatocellular carcinoma. Expression of MEG3 in tumor tissues and adjacent healthy tissues of hepatocellular carcinoma patients, as well as the serum of both hepatocellular carcinoma patients and healthy controls, was detected by quantitative reverse transcriptase-polymerase chain reaction. The results showed that expression level of MEG3 was significantly lower in tumor tissues than in adjacent healthy tissues. Serum level of MEG3 was also significantly lower in hepatocellular carcinoma patients than in normal controls. The receiver operating characteristic curve analysis was used to evaluate the diagnostic value of MEG3 for hepatocellular carcinoma, and the prognostic value of MEG3 for this disease was analyzed using Kaplan-Meier method. The results indicated that serum level of MEG3 was a diagnostic and prognostic marker for hepatocellular carcinoma. We also found that MEG3 small interfering Ribonucleic Acid (siRNA) silencing promoted the proliferation, migration, and invasion of hepatocellular carcinoma cells by CCK-8 assay, transwell migration, and invasion assay, respectively, while TGF-β inhibitor treatment reduced those enhancing effects. MEG3 siRNA silencing also increased the expression level of TGF-β1. These results indicated that downregulation of MEG3 can promote proliferation, migration, and invasion of human hepatocellular carcinoma cells by upregulating TGF-β1 expression.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  TGF-β1; hepatocellular carcinoma; lncRNA MEG3

Mesh:

Substances:

Year:  2019        PMID: 31089680     DOI: 10.1093/abbs/gmz046

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  6 in total

1.  Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B.

Authors:  Jiao Yin; Xiansheng Zhao; Xuejiao Chen; Guanxin Shen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

2.  The competitive endogenous RNA regulatory network reveals potential prognostic biomarkers for overall survival in hepatocellular carcinoma.

Authors:  Zhiqiao Zhang; Jing Li; Tingshan He; Yanling Ouyang; Yiyan Huang; Qingbo Liu; Peng Wang; Jianqiang Ding
Journal:  Cancer Sci       Date:  2019-08-07       Impact factor: 6.716

Review 3.  The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Bashdar Mahmud Hussen; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

Review 4.  Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities.

Authors:  Aditi Kulkarni; Sharan Gayathrinathan; Soumya Nair; Anamika Basu; Taslim A Al-Hilal; Sourav Roy
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

Review 5.  Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance.

Authors:  Ariadna Pielok; Krzysztof Marycz
Journal:  Int J Mol Sci       Date:  2020-06-11       Impact factor: 5.923

6.  The Association of MEG3 Gene rs7158663 Polymorphism With Cancer Susceptibility.

Authors:  Xueren Gao; Xianyang Li; Shulong Zhang; Xiaoting Wang
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.